Drugs Targeting NLRP3 Inflammasome in the Treatment of Diabetic Bone Disorders

CONCLUSION: The presented studies indicate that hyperglycemia is the initiating factor for NLRP3-induced bone disorders in diabetic patients. The main drug targets are the molecules relevant to the assembly and activation of NLRP3 inflammasome. These data may provide a theoretical basis for the further development of drugs targeting NLRP3 inflammasome in the treatment of diabetic bone disorders.PMID:36959134 | DOI:10.2174/1871530323666230320164235
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Authors: Source Type: research